==== Front Cell Mol ImmunolCell. Mol. ImmunolCellular and Molecular Immunology1672-76812042-0226Nature Publishing Group UK London 295531358410.1038/cmi.2018.4Review ArticleTLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy Huang Lan 12Xu Huaxi 2Peng Guangyong guangyong.peng@health.slu.edu 11 0000 0004 1936 9342grid.262962.bDivision of Infectious Diseases, Allergy and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, 63104 Saint Louis, MO USA 2 0000 0001 0743 511Xgrid.440785.aDepartment of Microbiology and Immunology, Jiangsu University School of Medicine, 212013 Zhenjiang, China 19 3 2018 19 3 2018 5 2018 15 5 428 437 7 9 2017 28 12 2017 29 12 2017 © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.Cellular energy metabolism not only promotes tumor cell growth and metastasis but also directs immune cell survival, proliferation and the ability to perform specific and functional immune responses within the tumor microenvironment. A better understanding of the molecular regulation of metabolism in different cell components in the tumor-suppressive microenvironment is critical for the development of effective strategies for human cancer treatments. Toll-like receptors (TLRs) have recently been recognized as critical factors involved in tumor pathogenesis, regulating both tumor cells and tumor-infiltrating innate and adaptive immune cells. However, little is known about the molecular crosstalk between TLR signaling and tumor or/and immune cell metabolism, although there is abundant expression of TLRs in these cells. In this review, we explore the functional role of TLR signaling in reprogramming cell metabolism in the tumor microenvironment. In particular, we discuss how malignant tumors regulate metabolism to support their growth and survival, summarize more recently identified metabolic profiles of different immune cell subsets and TLR-mediated regulation of cellular metabolism in both tumor and immune cells, and further explore potential strategies targeting cell metabolism for TLR-based cancer therapy. An improved understanding of these issues should open new avenues for the development of novel strategies via TLR-mediated metabolic reprogramming of the tumor microenvironment for cancer immunotherapy. Keywords checkpoint blockadeimmunotherapymetabolic reprogrammingtumor microenvironmentwarburg effectissue-copyright-statement© The Chinese Society of Immunology and The University of Science and Technology of China, All rights reserved 2018 ==== Body Introduction It is well established that the Warburg effect of aerobic glycolysis is a key metabolic hallmark of cancer. Malignant tumor cells selectively reprogram their metabolism to meet the rapid energy requirements for proliferation, survival and metastasis, as well as for sustaining the tumor-suppressive microenvironment.1,2,3,4,5 In addition to tumor cells, it is now well recognized that metabolic reprogramming occurs in all cell components within the tumor microenvironment that have hypoxic and acidotic conditions, including dendritic cells (DCs), macrophages and T cells.5,6 During normal activation, DCs and macrophages undergo a metabolic switch to glycolysis instead of oxidative phosphorylation (OXPHOS), which also directs the macrophage M1 or M2 phenotype switch.7,8,9 Tumor-associated macrophages (TAMs) have increased aerobic glycolysis with an inflammatory phenotype and protumorigenic effect.10,11,12 However, tumor-derived DCs with tolerogenic functions have inhibited glycolysis but increased lipid accumulation.13,14 Cellular energy metabolism also directs T-cell survival, proliferation and their specific functions.15,16,17,18,19 Aerobic glycolysis is the main metabolic pathway and is specifically required for effector function in T cells.4,15,19,20,21,22 By contrast, lipid oxidation has been found to be a primary metabolic pathway for induced Treg cells and memory CD8+ T cells.20,23,24,25 However, very limited information is known about how malignant tumors and tumor-derived microenvironmental factors affect different types of tumor-infiltrating T-cell (TIL) fate and metabolism. Recent studies have suggested that tumor cells can compete for glucose or restrict glycolysis in TILs within the tumor microenvironment, resulting in T-cell dysfunction and immune suppression.4,26,27,28 A better understanding of the molecular interactions and metabolic profiles of tumor cells and different types of immune cells within the tumor-suppressive microenvironment will facilitate the development of novel strategies for cancer therapy via metabolic reprogramming of cell fate and functions.29 Toll-like receptors (TLRs), the most well-known pattern recognition receptors, recognize molecules from invading pathogens and are important for innate immunity and inflammatory responses. It is now well recognized that TLR-mediated metabolic reprogramming is important for the activation, maturation and immunogenic functions of macrophages and DCs.7,30,31,32,33,34,35 TLRs are also widely expressed on different types of tumor cells, regulating tumor growth and functions.36,37,38 Studies from multiple preclinical animal models and clinical trials have shown that either promotion or inhibition of tumor survival and growth is mediated by different TLR stimulations in tumor cells.36,39,40,41 Recent studies suggest that TLRs directly regulate metabolism, affecting tumor behavior and function in melanoma, prostate, head and neck carcinoma and breast cancer.38,42,43,44 Furthermore, several TLR ligands, including imiquimod (TLR7) and CpG (TLR9), have shown significant promise for cancer treatment.39,45 Increasing evidence suggests that TLR signaling also affects the differentiation and function of different T-cell subsets, including Th1, Th2 and Th17 cells.46,47,48 Furthermore, human TLR8 signaling can directly reverse the suppressive function of tumor-derived CD4+, CD8+ and γδ Treg cells.49,50,51,52,53 However, whether and how TLR signaling regulates T-cell metabolism is still under investigation. Understanding functional and metabolic regulation in tumor cells and tumor-infiltrating immune cells mediated by different TLRs will be important for the development of novel TLR-based cancer immunotherapy. Energy metabolism directs tumor growth and metastasis In the tumor microenvironment, tumors prefer to use aerobic glycolysis instead of OXPHOS to meet their demands for growth and proliferation, especially for rapid ATP generation and biosynthesis54 (Table 1). During tumor growth with hypoxic stress in the microenvironment, hypoxia-inducible transcription factor (HIF) has a critical role in promoting the transcriptional program for this metabolic switch. HIF-1α induces expression of lactate dehydrogenase and pyruvate dehydrogenase kinase and facilitates the metabolic switch by binding to glucose transporter 1 (Glut1) and other glycolytic enzymes. This results in increased lactate production from pyruvate and limited acetyl-CoA production for the tricarboxylic acid (TCA) cycle promotion through inhibiting pyruvate dehydrogenase.55,56 The Warburg effect of cancer glycolysis occurs even in the presence of completely functional mitochondria, which significantly benefits cancer cell biosynthesis and survival. Aerobic glycolysis can also increase rapidly and maintain a higher ratio of ATP/ADP to assist the tumor to avoid apoptosis and promote proliferation than that obtained from mitochondrial respiration.2,3 In addition, glycolysis-derived metabolites, such as palmitate, NADPH and Acetyl-CoA, promote fatty-acid synthesis, cell membrane constitution and macromolecular precursor biosynthesis. Furthermore, the high rates of glycolysis in cancer cells also help their competition with TILs in the tumor microenvironment for the limited glucose, resulting in suppression of the TIL effector function and maintenance of a suppressive microenvironment.4,5 In addition to the involvement of the transcription factor HIF, many oncogenes directly regulate the metabolic rewriting of cancer cells. For example, mutated KRAS drives metabolic reprogramming of lung cancer and nutrient uptake.57 Mutated c-Myc increases the transcriptional activities of enzymes in glycolysis and glutaminolysis, contributing to tumor growth and chemoresistance.58,59 p53 expression in tumor cells also controls metabolic genes and alters glucose utilization.60 In addition to their dominant glycolysis and increased glucose metabolism, malignant tumor cells may utilize other metabolic pathways, such as fatty-acid oxidation and cholesterol synthesis, to meet their requirements for synthesizing macromolecules, such as nucleic acids, lipids and proteins, during their growth and metastasis processes.61,62 Therefore, an improved understanding of the molecular processes of tumor metabolism will facilitate the design of effective therapeutics that specifically target cancer metabolic programming. Table 1 Summary of the metabolic profiles of tumor cells and immune cells Cell types Metabolic profiles References Tumors Glucose metabolism: glycolysis↑ (ATP/ADP and NAD+/NADH↑), HIF-1α↑, Akt↑, Glut1↑;Lipid metabolism: de novo lipid synthesis↑, fatty-acid and membrane lipid synthesis↑, cholesterol synthesis↑;Amino-acid metabolism: protein synthesis↑; levels of amino acid transporters↑, serine and glycine synthesis↑, glutamine↑;Metabolites↑: lactate, cAMP, IDO and adenosine 2, 3, 54, 59, 68, 123 DCs Activation-induced Warburg metabolism:Glucose metabolism: glycolysis↑, HIF-1α↑, Glut1↑, iNOS and ROS↑, lactate↑, u-PFK2↑, OXPHOS↓;Lipid metabolism: de novo synthesis of fatty acids↑, AMPK activation↓, FAO and mitochondrial biogenesis↓;Amino-acid metabolism: cystine uptake and cysteine production↑Others: activation of PI3K, TBK1 and IKKɛ signaling; succinylation of GAPDH, MDH, LDHA, glutamate carrier 1 and multiple proteins.Tolerogenic DCs: OXPHOS↑ and lipid accumulation 7, 13, 14, 30, 80, 109 Macrophages Activation-induced metabolism:Glucose metabolism: glycolysis↑, HIF-1α↑, Glut1↑, iNOS, NO and ROS↑, lactate↑, u-PFK2↑, OXPHOS↓;Lipid metabolism: lipid biosynthesis↑, AMPK activation↓, FAO↓;Amino-acid metabolism: cellular arginine↑ and citrulline↑.‘M1 macrophages’: glycolysis↑, fatty-acid synthesis↑, citrulline↑, iNOS/NO↑, HIF-1α↑, u-PFK2↑, mTOR↑;‘M2 macrophages’: OXPHOS↑, NO↓, Arg-1↑, PFKFB1↑, AMPK↑ 7, 33, 77 Activated T cells Glucose metabolism: glycolysis and lactate production↑, Glut1↑, PPP↑, glutamine uptake↑, pyruvate oxidation through TCA cycle↓;Lipid metabolism: de novo fatty acid↑, FAO↓; Amino-acid metabolism: amino-acid transporter level (Slc7a5) ↑ 19, 81, 84 Th1/Th2/Th17 cells Glycolysis↑, Glut1↑, lactate production↑, HIF-1 α↑; mTORC1 activity (Th1 and Th17)↑ and mTORC2 activity (Th2)↑; de novo fatty-acid synthesis↑; amino acid (glutamine and leucine) ↑ 19, 62, 81 Treg cells Glycolysis↑, glucose uptake↑, AMPK activation↑, mTORC1↓; FAO↑ and lipogenesis↑; glutamine and leucine↑, amino-acid-catabolizing enzymes ARG1, HDC, TDH and IL-4I1↑; IDO↑; tryptophan catabolism (Kynurenine)↑ 18, 19, 62 Abbreviations: AMPK, AMP-activated protein kinase; Arg-1, arginase 1; DC, dendritic cell; Glut1, glucose transporter 1; FAO, Fatty acid β-oxidation; HDC, Histidine decarboxylase; HIF, hypoxia-inducible transcription factor; IDO, indoleamine 2, 3-dioxygenase; IL4I1, Interleukin 4 induced 1; iNOS, inducible nitric oxide synthase; IKKɛ, Inhibitor-κB kinase ɛ; LDHA, Lactate dehydrogenase A; MDH, malate dehydrogenase; NO, nitric oxide; OXPHOS, oxidative phosphorylation; PFKFB-1, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1; PI3K, Phosphoinositide 3-kinase; ROS, reactive oxygen species; TBK1, Serine/threonine-protein kinase 1; TCA, tricarboxylic acid; TDH, Threonine dehydrogenase; Treg, regulatory T cell; u-PFK2, u-Phosphofructokinase 2. Tumor-derived metabolites maintain a potent tumor-suppressive microenvironment Malignant tumors display heightened glucose and glutamine consumption, resulting in the depletion of nutrients and competition with different types of tumor-infiltrating immune cells.4,5 Meanwhile, metabolic end products are also accumulated within the tumor microenvironment, including cyclic adenosine monophosphate (cAMP), indoleamine 2, 3-dioxygenase (IDO), adenosine and lactate.63 These hypoxia-derived metabolites are potent immune suppressors that can protect tumor cells from T-cell-mediated antitumor immune responses, which is one of the strategies utilized by tumor cells to create an immunosuppressive micromilieu and escape the host immune system.63,64,65 Lactate is the main metabolite of glycolysis utilized by malignant tumor cells (Warburg effect).66,67 Increased lactate production supports NAD+ regeneration in the absence of oxygen consumption and may provide other benefits to tumor cells related to altered pH, which leads to an acidified tumor microenvironment and cancer cell invasion.68 Tumor-derived lactate blocks differentiation and activation of monocytes and promotes M2 TAM polarization.69,70 Furthermore, intracellular lactate can trigger T cell and NK cell suppression and impair their tumor immunosurveillance functions.71,72 More recent studies have indicated that tumor-derived lactate promotes naive T-cell apoptosis through suppression of FAK family-interacting of 200 kDa (FIP200) and autophagy in ovarian cancer patients.28 cAMP is also a critical component of the tumor-induced hypoxic microenvironment and is a potent inhibitor of effector tumor-specific T cells.63 Furthermore, cAMP is involved in Treg-mediated suppression and is a potent inhibitor of interleukin (IL)-2 production and subsequent CD4+ T-cell proliferation.73,74 Recent studies have demonstrated that different types of tumor cells can directly induce conversion from naive/effector T cells to senescent T cells with potent suppressive activity.38,44 These studies have further identified that high concentrations of cAMP exist in tumor cells and tumor-induced senescent T cells and that tumor-derived endogenous cAMP is responsible for the induction of T-cell senescence.38,44 Adenosine is another important metabolite in tumor hypoxic microenvironments.63,75 Tumor-produced adenosine triggers immunosuppressive signaling via intracellular cyclic AMP, elevating A2A adenosine receptors on antitumor T cells. Furthermore, tumor-infiltrating Treg cells undergo apoptosis and generate adenosine to suppress T-cell-mediated tumor immunity through the A2A pathway.75 IDO expressed in tumors depletes tryptophan and inhibits T-cell proliferation.76 A better definition of the mechanistic links between tumor immunosuppression, hypoxia and metabolic dysregulation should lead to novel and alternative strategies that are capable of augmenting immune responses directly against cancer. Metabolic regulation is crucial for immune cell development and functions Metabolic programming also occurs in immune cell components in the tumor microenvironment. The Warburg effect is utilized by innate immune cells, including macrophages and DCs (Table 1). Activation of macrophages with different types of stimuli, such as TLR ligands, IFN-γ and certain pathogens, drives a metabolic switch from OXPHOS to glycolysis.7,30,31,32,33 Macrophages are classified into two groups, M1 and M2, based on the stimuli and their functions. M1 macrophages activated by classical stimuli, such as TLR ligands and bacteria, possess an inflammatory phenotype and affect an antitumor function. M2 microphages, polarized by IL-4 and IL-13, have an anti-inflammatory phenotype and have pro-tumoral activity.33,77 Recent studies have clearly shown that M1 and M2 macrophages have different metabolic profiles. M1 macrophages rely on glycolysis for ATP production and their increased fatty-acid synthesis, whereas M2 macrophages are supported by fatty-acid uptake and OXPHOS in the mitochondria to produce ATP.7,33 In addition, M1 macrophages have increased levels of inducible nitric oxide synthase (iNOS), HIF-1α and u-Phosphofructokinase 2, whereas M2 macrophages have increased levels of arginase 1, AMP-activated protein kinase and 6-phosphofructo-2-kinase/fructose-2,6-biSphosphatase 1.7,33 Macrophages are dominant innate immune cells in the tumor-suppressive microenvironment. TAMs have increased aerobic glycolysis with an inflammatory phenotype and pro-tumorigenic effects, which might be induced by enhanced HIF-1α.10,11,12 DCs have a very similar metabolic profile as macrophages. DCs activated by TLR agonists undergo a marked metabolic reprograming that is characterized by a switch from mitochondrial lipid oxidation and OXPHOs to increased aerobic glycolysis.7,30,34,35 Therefore, glycolysis is also important for DC activation, maturation and immunogenic functions. However, tolerogenic DCs, similar to M2 macrophages, have a distinct metabolic profile from immunogenic DCs with increased mitochondrial metabolism and OXPHOS.34,78 Tolerogenic DCs display immature and inactivated phenotypes and favor Treg induction and immune suppression.79,80 In addition, tumor-derived DCs with tolerogenic functions have inhibited glycolysis, but increased lipid accumulation, resulting in impaired APC functions and T-cell priming.13,14 Significant progress has been made in understanding T-cell metabolism over the last several years. It is now recognized that cellular energy metabolism directs T-cell survival, proliferation and their specific functions15,16,17,18,19 (Table 1). Resting T cells generate their energy using TCA to meet their limited biosynthesis. Activated T cells require more nutrients to supply them with an appropriate amount of energy from a sufficient biomass, and glucose and amino-acid metabolism are increased.81 Activated CD4+ T cells increase both glycolysis and fatty-acid metabolism, whereas CD8+ T cells dominantly shift metabolism to glycolysis to rapidly produce ATP.81,82,83 Mitochondrial fatty-acid oxidation is also required for the generation of memory T cells.24 In naive and memory T cells, stimulation of TCR and CD28 drives T-cell metabolic reprogramming, which is controlled by the transcription factor c-Myc that regulates the expression of glucose and glutamine transporters instead of HIF.84 mTOR upregulation of c-Myc and HIF is responsible for the maintenance of glycolytic activity during the process of T-cell activation.84 Notably, different T cell subsets have different metabolic profiles.16,17,18,19 Aerobic glycolysis is the main metabolic pathway and is specifically required for T cell effector function upon activation.4,15,19,20,21,22 By contrast, lipid oxidation has been found to be the primary metabolic pathway for induced Treg cells and memory CD8+ T cells.20,23,24,25 Furthermore, endogenous fatty acid synthesis and the glycolytic-lipogenic axis are important for Th17 cell development.85 In addition, both glycolysis and lipid metabolism regulate Treg differentiation, stability and homeostasis, as well as suppressive its activity.18,20,23,86,87,88,89 Several molecular signaling pathways and/or molecules, including AKT-mTOR signaling, TLR signaling, as well as the transcription factors HIF1α, c-Myc and FoxP3, have been shown to directly regulate Treg metabolic programming and development.18,23,84,86,87,88,90 Given that TILs are dysfunctional and that metabolism directs the T-cell fate and function, defining the metabolic processes of different subsets of T cells should provide alternative novel strategies for breaking the immune tolerance induced by the tumor-suppressive microenvironment. TLR signaling involves metabolic reprogramming in tumor cells TLRs recognize pathogen-associated molecular patterns and are critical components of the innate immune system, acting as a link between innate and adaptive immunity to orchestrate pathogen infections and inflammatory responses. In addition to immune cells, TLRs are also widely expressed on different types of tumor cells, regulating tumor growth and function, directly or indirectly, as a ‘double-edged sword’.36,37,38 Several TLR ligands, such as the TLR7 agonist imiquimod, TLR3 ligand Poly (I:C) and TLR9 ligand CpG, can directly induce TLR-positive tumor cell apoptosis or enhance tumor-infiltrating innate and tumor-specific T-cell function.39,45,91,92 By contrast, signaling through TLR2 and TLR5 can enhance the proliferation and survival of gastric cancer cells, promoting the effects of tumor metastasis.93,94,95 Lipopolysaccharide (LPS; TLR4) and Loxoribine (TLR7) favor tumor development and survival.96,97 In addition, increased expression of TLR9 seems to have a close relationship with tumor proliferation in oral squamous cell carcinoma patients, and upregulation and activation of TLR4 is associated with tumor relapse, metastasis and chemoresistance in colorectal and pancreatic cancers.41,98,99,100,101,102 Identifying the unique signaling pathways in tumor cells mediated by different TLRs will be important for exploring the molecular mechanisms involved in cancer immunopathogenesis, as well as for the development of novel TLR-based therapy for human cancer. More recent studies suggest that TLRs may directly regulate cell metabolism, affecting tumor behaviors and functions (Table 2). Stimulation with the TLR3 ligand Poly (A:U) promotes metabolic reprograming of head and neck carcinoma cells, resulting in increased tumor growth.42 TLR3 induces tumor cells to switch from OXPHOS and TCA to anabolic glycolysis, showing an enhanced extracellular acid cation rate (ECAR) and lactate accumulation. The TLR3-mediated metabolic switch in cancer cells involves the transcription factor HIF-1α and hypoxic regulation, suggesting that TLR3 signaling may benefit tumors to adapt to hypoxia in the tumor microenvironment.42 Furthermore, TLR9 has been suggested to regulate lipid peroxidation and trace elements (selenium, copper, zinc, magnesium and iron) in response to oxidative stress in patients with breast diseases and breast carcinoma.43 In addition to directly affecting tumor metabolic reprograming and tumor growth, TLRs can regulate cancer cell metabolites, indirectly influencing antitumor immune responses in the tumor microenvironment. Recent studies have shown that human tumor cells can convert naive/effector T cells into senescent T cells to induce immune tolerance, which is molecularly dependent on tumor-derived endogenous metabolic cAMP.38,44 Notably, activation of TLR8 signaling in tumor cells can prevent cAMP production by tumor cells and block tumor-induced conversion of naive and tumor-specific T cells into senescent cells, resulting in enhanced antitumor immunity in vivo.38,44 In addition to the regulation of cAMP, TLR can regulate another key metabolite, IDO, during cancer immunotherapy. Administration of a TLR7 agonist, imiquimod, significantly increases IDO expression in tumor-draining lymph nodes, which inhibits tumor antigen-specific immune responses. Inhibition of IDO expression after TLR7 agonist administration could enhance the efficacy of TLR-mediated therapy.103 TLR agonists can induce enhanced expression of IDO in various cells in addition to tumor cells.104,105 These studies provide mechanistic links between innate regulation via TLR signaling, tumor immunosuppression, hypoxia and metabolic dysregulation. Table 2 TLR-mediated metabolic reprogramming in different types of cells TLRs Ligands Metabolic reprogramming and functional alterations References TLR1 Pam3CSK4;Triacryl lipopeptide Treg cells: promote glycolysis, but impair their suppression; increase Glut1 and HK2 expression as well as lactate production 90 TLR2 Heat-killed PAPam3CSK4 DCs: induce a rapid increase in glycolysis and glucose consumption; promote glycolysis-fueled synthesis of fatty acids and DC activation.Macrophages: activate the transcription factor CREB to regulate IL-10 production and promote glycolysis as well as decrease the TCA and oxidative phosphorylation; upregulate MCT-4 for macrophage activation.Treg cells: promote glycolysis, but impair their suppression. increased expression of Glut1 and HK2 as well as lactate production; lose the Treg suppressive phenotype in the presence of TCR stimulation and suppress Foxp3 expression 30, 90, 113, 114 TLR3 Poly (A:U); Poly(I:C); dsRNA Head and neck carcinoma cells: increase glycolysis and lactate production; promote amino-acid synthesis, HIF-1α activity and PPP; and decrease the level of TCA 42 TLR4 LPS DCs: induce a rapid increase in glycolysis, glucose consumption andiNOS as well as promote fatty-acid synthesis and FAO; decrease OXPHOS; promote DC activation.Macrophages: activate the transcription factor CREB to regulate IL-10 production and promote glycolysis; decrease the TCA and oxidative phosphorylation; upregulate MCT-4 for macrophage activation 30, 34, 109, 113, 116 TLR7 Imiquimod andLoxoribine PDCs: promote early glycolysis in human blood-derived PDC; increase ECAR and Glut1 expression.Tumor cells and tumor-draining lymphocytes: increase the metabolite IDO 103, 111 TLR8 Poly-G3 Cancer cells: decrease the level of cAMP and prevent tumor-induced senescence in T cells 38 TLR9 CpG Breast cancer: regulate the levels of trace elements and lipid peroxidation during oxidative damage.DCs: induce a rapid increase in glycolysis, glucose consumption and iNOS; promote fatty-acid synthesis and FAO; decrease OXPHOS; promote DC activation.PDCs: promote late glycolysis (after 24 h) in mouse bone marrow-derived PDC via a type I IFN/IFNAR loop and PDC activation; induce FAO coupled with OXPHOS to generate ATP in a PPARα-dependent mechanism; activate mTORC1 43, 110, 111 Abbreviations: CREB, cAMP response element binding; DC, dendritic cell; EACR, extracellular acid cation rate; FAO, Fatty acid β-oxidation; HIF, hypoxia-inducible transcription factor; HK2, hexokinase 2; IDO, indoleamine 2, 3-dioxygenase; IFN, interferon; IFNAR, The interferon-α receptor; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; OXPHOS, oxidative phosphorylation; PDC, plasmacytoid dendritic cell; PPP, Pentose phosphate pathway; TCA, tricarboxylic acid; TLR, Toll-like receptor; Treg, regulatory T cell. TLR-mediated metabolic switch is critical for the activation and immunogenic function of macrophages and DCs Metabolic reprograming to quickly produce ATP and energy is required for infectious pathogen-mediated activation of macrophages and DCs. It is well established that stimulation with TLR ligands from pathogens, such as LPS, can promote a metabolic switch from OXPHOS to glycolysis in macrophages, resulting in cell activation and development of M1 macrophages with inflammatory phenotypes and effector functions.7,30,31,32,33 Similarly, TLR-induced activated DCs have increased glycolysis and reduced OXPHOS.7,30,34,35 The TLR-mediated metabolic switch to glycolysis is also required for DC maturation, allowing them to acquire immunogenic functions and survive after activation.7,34,35 Several key molecules are involved in the activation of macrophages and DCs. Upon stimulation by LPS via TLR4, increased production of iNOS and nitric oxide are important for inhibition of the molecular processes toward OXPHOS.7,106 In addition, the AKT–mTOR–HIF-1α pathway controls metabolic programming and glycolysis during TLR-mediated activation of macrophages and DCs.107,108 Furthermore, recent studies have suggested that TLR-driven early glycolytic programming occurs through rapid phosphorylation and activation of the kinases AKT, TBK1 and IKKɛ, which promote the activity of glycolytic enzymes and de novo synthesis of fatty acids to support DC activation.30,109 In addition to the promotion of glycolysis for cell activation, different TLRs may have diverse biological effects on metabolic regulation in DCs and macrophages. More recent studies have shown that TLR7 and TLR9 signaling can trigger both glycolysis and lipid metabolism in plasmacytoid dendritic cells (PDCs).110,111 In mouse PDCs, TLR9 promotes late glycolysis via a type I IFN/IFNαR loop, resulting in increased fatty-acid synthesis and cholesterol metabolism.110,111 In human PDCs, TLR7 signaling triggers early glycolysis and increased ECAR, which occurs through HIF1α-mediated enhanced expression and the activity of glucose transporters and glycolytic enzymes.110 Furthermore, although stimulation with TLR2 and TLR4 ligands can promote metabolic reprogramming to glycolysis in macrophages, and LPS stimulation leads to a decrease in OXPHOS, whereas stimulation with Pam3CysSK4 can increase the oxygen consumption and mitochondrial enzyme activity involved in the upregulation of both glycolysis and OXPHOS.112,113 These studies indicate that TLR signaling is a critical trigger to control the innate immune cell fate and their functions (Table 2). TLR-mediated metabolic switch regulates T-cell subset development and function TLR signaling is also important for regulating the subset development, differentiation and functions of T cells.46,47 TLR2 signaling can directly enhance both proliferation and IL-17 production by Th17 cells and promote the pathogenesis of EAE.46 Activation of TLR2 can also promote and generate efficient memory T cells by producing more IFN-γ and granzyme B and enhancing the cytotoxic activity of antigen-activated CD8+ T cells.114 TLR2 signaling in DCs or Treg cells can reverse mouse Treg suppression.115,116 The TLR3 ligand Poly (I:C) and TLR9 ligand CpG can stimulate Th1 responses and mediate potent antitumor activity.47 TLR4 activation in CD4+ T cells is essential for the proliferation and survival of Th1 and Th17 cells and stimulates IL-17 production.47,117 Activation of TLR4 in CD4+CD25+ Treg cells by LPS can also directly induce Treg cell activation and promote cellular survival and proliferation.118 More recent studies have identified that TLR7 signaling activation in T cells can inhibit both Th17 and Th1 cell differentiation and function, but through different molecular mechanisms. These studies further revealed that inhibition of STAT3 signaling is responsible for TLR7-mediated suppression of Th17 cells, which is reciprocally regulated by the induction of SOCS3 and SOCS5.48 In addition, human TLR8 signaling directly reverses the suppressive functions of naturally occurring CD4+CD25+ Treg cells as well as tumor-derived CD4+, CD8+ and γδ Treg cells.49,50,51,52,53 Furthermore, various TLR signaling promotes chemoattraction and generation of Th17 cells in the tumor microenvironment through tumor cells and tumor-derived fibroblasts.37 Therefore, precisely dissecting the unique signaling pathways involved in the regulation of T-cell subsets by different TLRs will be important for the development of TLR-based tumor immunotherapy. Although increasing and new evidence suggests that energy metabolism directs the development and functions of T cells,15,16,17,18,19 very limited information is known about the causative relationship between innate regulation through TLR signaling and T-cell metabolism and functionality (Table 2). Given that TLR signaling is also important for regulating the biology and functions of T cells, an improved understanding of the molecular basis of their crosstalk is urgent for the field of tumor immunotherapy. It has been shown that activation of TLR2 and TLR7 signaling promotes the production of IFN-γ by murine CD8+ T cells, which is mechanistically dependent on activating PI3K–AKT–mTOR signaling. This molecular action requires energy support from mitochondrial respiration rather than glycolysis mediated by TLR signaling.119 However, a more recent study suggested that TLR1 and TLR2 signaling activation in mouse Treg cells increases Treg glycolysis and proliferation, but reduces their suppressive capacity.90 TLR1/2-mediated signaling in Treg cells is also involved in the activation of PI3K–AKT–mTOR signaling and enhances expression of Glut1 and the glycolytic enzyme hexokinase 2 (HK2) in Treg cells.90 Studies from our group have demonstrated that TLR8 signaling directly reverses the suppressive functions of different types of human Treg cells, including CD4+, CD8+ and γδ Treg cells.49,50,51,52,53 TLR8-mediated reversal of Treg suppression significantly enhances antitumor immunity for tumor immunotherapy.38,49 We have also shown that tumor-derived cAMP can induce naive and effector T-cell senescence, resulting in impaired antitumor immunity.38 In addition, TLR8 signaling suppresses tumor cell metabolism, resulting in downregulated cAMP levels in both tumor cells and senescent T cells.38 Given that both glucose and lipid metabolism are required for Treg suppression89 and that cAMP is a key component of Treg cell suppression,73 we propose that TLR8 signaling in human Treg cells could also regulate Treg metabolism to inhibit Treg-suppressive activity. Future studies will facilitate our understanding of the molecular mechanisms that are involved in TLR8 signaling-based immunotherapy targeting both tumors and Treg cell metabolic reprogramming. Rethinking TLR-based tumor immunotherapy by targeting metabolic reprogramming in the tumor microenvironment Although several TLR agonists have been developed as immunotherapeutic drugs for use in cancer treatments, the results from clinical trials thus far have been discouraging.39,40,120 The varied effects mediated by TLR agonists on different cell types in the tumor microenvironment might be a reason for the insufficient antitumor effects that were found during patient treatment. Therefore, defining the unique molecular signaling/mechanism(s) induced by each TLR on different cell components is essential for improving TLR-mediated antitumor immunity. Recently, significant progress has been made in understanding the importance of metabolic reprogramming/switching for both tumor cells and immune cells in the tumor microenvironment, especially in different types of T cells. Furthermore, recently, many of the molecular interactions involved in TLR signaling and metabolic regulations have been identified and have been focused on by research groups. The updated information and knowledge of cellular metabolism and TLR research not only markedly facilitates our understanding of human immunity under both physiological and pathological conditions but also provides insights for us to rethink the novel and effective TLR-mediated tumor immunotherapeutic strategies that target metabolic reprogramming of both tumor and immune cells within the tumor microenvironment. The following key issues should be reconsidered when we design TLR-based immunotherapy. (a) Understand the dual effects on tumor metabolism mediated by TLRs. We first need to reconsider the fact that TLRs are a ‘double-edged sword’ with both pro-tumorigenic and antitumor effects.36,37,38 We should consider that some TLR signaling can directly promote tumor growth and metastasis by regulating their metabolic reprogramming.42,43 In addition, TLR signaling can regulate metabolites produced by tumor cells, such as cAMP and IDO, which are potent immune suppressors, maintaining the tumor-suppressive microenvironment.63,64,65 Therefore, identification of selective TLR agonists that specifically inhibit tumor metabolism and/or regulate tumor-derived metabolites is needed for TLR-based tumor vaccine/therapy. (b) Metabolically control the balance between Treg and effector T cells via suitable TLR signaling in the tumor microenvironment. It has become clear that a significant challenge in the design of novel cancer immunotherapies is to develop effective strategies for breaking the immune tolerance induced by Treg cells and regenerating the balance between tumor-specific effector T cells and Treg cells in the tumor microenvironment.121 An improved understanding of the distinct metabolic processes of Treg cells and effector T cells will provide alternative and more specific targets for controlling Treg-induced immune suppression by regulating T-cell metabolism. In addition, recent studies have shown that certain types of TLR agonists, such as TLR1/2 and TLR8, can reverse Treg suppression by regulating Treg metabolism.49,50,51,52,53,90 These studies strongly support the concept that TLR-mediated reprogramming of T-cell metabolism is a novel and feasible strategy for tumor immunotherapy. (c) Functional reconstitution of macrophages and DCs in the tumor microenvironment via TLR-mediated metabolic reprogramming. Effector functional reconstitution of macrophages and DCs in tumor sites via metabolic reprogramming through TLRs is also a potential future therapeutic approach. TAMs and tolerogenic DCs are critical cell components within the tumor-suppressive microenvironment. Both TAMs and tolerogenic DCs have distinct metabolic profiles from immunogenic macrophages and DCs.10,11,12,13,14 Developing effective strategies using the TLR-mediated metabolic switch to promote the activation and immunogenic functions of macrophage and DCs in the tumor microenvironment are also essential for tumor immunotherapy. (d) Select effective combinations of other therapeutic strategies with a TLR-based cancer treatment. It has been shown that TLR agonists that are used as a single type of antitumor drug have yielded limited success in clinical trials.40 Combined use of TLR agonists with other therapeutic strategies should be considered in the future for cancer treatments. In support of this concept, checkpoint blockage therapy with PD1/PDL1 and CTLA4 can change the metabolic balance between tumors and TILs and enhance tumor immunotherapy.29,122 Furthermore, recent studies have suggested that TLR8 signaling in tumor cells significantly downregulates tumor-derived metabolite cAMP, which induces T-cell senescence and immune suppression.38,44 Combined application of the TLR8 agonist and an adoptive transfer of T-cell therapy markedly prevents tumor-specific T-cell senescence and promotes their antitumor efficacy in vivo.38,44 Therefore, we propose that TLR-mediated metabolic reprogramming of the tumor microenvironment combined with adoptive T-cell therapy and/or checkpoint blockade therapy that targets both tumor and T cells and creates an effective condition favoring and enhancing antitumor immune responses should be an emerging concept for cancer immunotherapy.6,29 Conclusions The tumor-suppressive microenvironments created by malignant tumors are a major obstacle for effective antitumor immunity and successful tumor immunotherapy. Cellular energy metabolism controls the fate and biological functions of both malignant tumor cells and tumor-infiltrating immune cells in the tumor microenvironment. The recently improved understanding of the metabolic profiles of different cell components, especially T-cell subsets, facilitates the development of novel strategies to reprogram cell metabolism for tumor immunotherapy. TLRs are widely expressed in both tumor cells and tumor-infiltrating immune cells and are involved in the regulation of tumor pathogenesis and antitumor immune responses. Increasing evidence strongly indicates that TLR signaling directly crosstalks with the molecular processes of cell metabolism in tumor cells and/or different subsets of immune cells. This more recent information will facilitate a rethinking of the novel role and therapeutic potential of TLR signaling in the tumor microenvironment. A better understanding of the mechanistic regulation of TLR signaling and metabolism in different cell components in the tumor-suppressive microenvironment should open new avenues for the development of novel strategies via TLR-mediated metabolic reprogramming for cancer immunotherapy. Acknowledgements We apologize since we cannot cite all of the relevant references in this research area because of space limitations. This work was partially supported by grants from the American Cancer Society (RSG-10-160-01-LIB, to GP), Melanoma Research Alliance (to GP) and the NIH (AI097852, AI094478 and CA184379 to GP). Conflict of interest The authors declare no conflict of interest. ==== Refs References 1 Pavlova NN Thompson CB The emerging hallmarks of cancer metabolism Cell Metab 2016 23 27 47 26771115 2 Liberti MV Locasale JW The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016 41 211 218 26778478 3 Vander Heiden MG Cantley LC Thompson CB Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009 324 1029 1033 19460998 4 Chang CH Qiu J O'Sullivan D Buck MD Noguchi T Curtis JD Metabolic competition in the tumor microenvironment is a driver of cancer progression Cell 2015 162 1229 1241 26321679 5 Lyssiotis CA Kimmelman AC Metabolic interactions in the tumor microenvironment Trends Cell Biol 2017 27 863 875 28734735 6 Reina-Campos M Moscat J Diaz-Meco M Metabolism shapes the tumor microenvironment Curr Opin Cell Biol 2017 48 47 53 28605656 7 Kelly B O'Neill LA Metabolic reprogramming in macrophages and dendritic cells in innate immunity Cell Res 2015 25 771 784 26045163 8 Granucci F Lutz MB Zanoni I The nature of activatory and tolerogenic dendritic cell-derived signal 2 Front Immunol 2014 5 42 24567734 9 Jha AK Huang SC Sergushichev A Lampropoulou V Ivanova Y Loginicheva E Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization Immunity 2015 42 419 430 25786174 10 Arts RJ Plantinga TS Tuit S Ulas T Heinhuis B Tesselaar M Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages Oncoimmunology 2016 5 e1229725 28123869 11 Penny HL Sieow JL Adriani G Yeap WH See Chi EeP San Luis B Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma Oncoimmunology 2016 5 e1191731 27622062 12 Wenes M Shang M Di Matteo M Goveia J Martin-Perez R Serneels J Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis Cell Metab 2016 24 701 715 27773694 13 Ramakrishnan R Tyurin VA Veglia F Condamine T Amoscato A Mohammadyani D Oxidized lipids block antigen cross-presentation by dendritic cells in cancer J Immunol 2014 192 2920 2931 24554775 14 Herber DL Cao W Nefedova Y Novitskiy SV Nagaraj S Tyurin VA Lipid accumulation and dendritic cell dysfunction in cancer Nat Med 2010 16 880 886 20622859 15 Macintyre AN Gerriets VA Nichols AG Michalek RD Rudolph MC Deoliveira D The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function Cell Metab 2014 20 61 72 24930970 16 Pearce EL Metabolism in T cell activation and differentiation Curr Opin Immunol 2010 22 314 320 20189791 17 Zeng H Chi H Metabolic control of regulatory T cell development and function Trends Immunol 2015 36 3 12 25248463 18 Newton R Priyadharshini B Turka LA Immunometabolism of regulatory T cells Nat Immunol 2016 17 618 625 27196520 19 MacIver NJ Michalek RD Rathmell JC Metabolic regulation of T lymphocytes Annu Rev Immunol 2013 31 259 283 23298210 20 Michalek RD Gerriets VA Jacobs SR Macintyre AN MacIver NJ Mason EF Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets J Immunol 2011 186 3299 3303 21317389 21 Chang CH Curtis JD Maggi LB Jr. Faubert B Villarino AV O'Sullivan D Posttranscriptional control of T cell effector function by aerobic glycolysis Cell 2013 153 1239 1251 23746840 22 Sukumar M Liu J Ji Y Subramanian M Crompton JG Yu Z Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function J Clin Invest 2013 123 4479 4488 24091329 23 Shi LZ Wang R Huang G Vogel P Neale G Green DR HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells J Exp Med 2011 208 1367 1376 21708926 24 Pearce EL Walsh MC Cejas PJ Harms GM Shen H Wang LS Enhancing CD8 T-cell memory by modulating fatty acid metabolism Nature 2009 460 103 107 19494812 25 Buck MD O'Sullivan D Klein Geltink RI Curtis JD Chang CH Sanin DE Mitochondrial dynamics controls T cell fate through metabolic programming Cell 2016 166 63 76 27293185 26 Sukumar M Roychoudhuri R Restifo NP Nutrient competition: a new axis of tumor immunosuppression Cell 2015 162 1206 1208 26359979 27 Zhao E Maj T Kryczek I Li W Wu K Zhao L Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction Nat Immunol 2016 17 95 103 26523864 28 Xia H, Wang W, Crespo J, Kryczek I, Li W, Wei S et al. Suppression of FIP200 and autophagy by tumor-derived lactate promotes naive T cell apoptosis and affects tumor immunity. Sci Immunol 2017; 2 doi:10.1038/10.1126/sciimmunol.aan4631. 29 O'Sullivan D Pearce EL Targeting T cell metabolism for therapy Trends Immunol 2015 36 71 80 25601541 30 Krawczyk CM Holowka T Sun J Blagih J Amiel E DeBerardinis RJ Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation Blood 2010 115 4742 4749 20351312 31 Pantel A Teixeira A Haddad E Wood EG Steinman RM Longhi MP Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation PLoS Biol 2014 12 e1001759 24409099 32 Qualls JE Subramanian C Rafi W Smith AM Balouzian L DeFreitas AA Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1 Cell Host Microbe 2012 12 313 323 22980328 33 Geeraerts X Bolli E Fendt SM Van Ginderachter JA Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity Front Immunol 2017 8 289 28360914 34 Everts B Pearce EJ Metabolic control of dendritic cell activation and function: recent advances and clinical implications Front Immunol 2014 5 203 24847328 35 Dong H Bullock TN Metabolic influences that regulate dendritic cell function in tumors Front Immunol 2014 5 24 24523723 36 Huang B Zhao J Unkeless JC Feng ZH Xiong H TLR signaling by tumor and immune cells: a double-edged sword Oncogene 2008 27 218 224 18176603 37 Su X Ye J Hsueh EC Zhang Y Hoft DF Peng G Tumor microenvironments direct the recruitment and expansion of human Th17 cells J Immunol 2010 184 1630 1641 20026736 38 Ye J Ma C Hsueh EC Dou J Mo W Liu S TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence EMBO Mol Med 2014 6 1294 1311 25231413 39 Smits EL Ponsaerts P Berneman ZN Van Tendeloo VF The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy Oncologist 2008 13 859 875 18701762 40 Ridnour LA Cheng RY Switzer CH Heinecke JL Ambs S Glynn S Molecular pathways: toll-like receptors in the tumor microenvironment—poor prognosis or new therapeutic opportunity Clin Cancer Res 2013 19 1340 1346 23271799 41 Yu L Wang L Chen S Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions Biochim Biophys Acta 2013 1835 144 154 23232186 42 Veyrat M Durand S Classe M Glavan TM Oker N Kapetanakis NI Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells Oncotarget 2016 7 82580 82593 27791989 43 Karki K Pande D Negi R Khanna S Khanna RS Khanna HD Correlation of serum toll like receptor 9 and trace elements with lipid peroxidation in the patients of breast diseases J Trace Elem Med Biol 2015 30 11 16 25744504 44 Ye J Peng G Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy Oncoimmunology 2015 4 e994398 25949919 45 Kanzler H Barrat FJ Hessel EM Coffman RL Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists Nat Med 2007 13 552 559 17479101 46 Reynolds JM Pappu BP Peng J Martinez GJ Zhang Y Chung Y Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease Immunity 2010 32 692 702 20434372 47 Shi G Vistica BP Nugent LF Tan C Wawrousek EF Klinman DM Differential involvement of Th1 and Th17 in pathogenic autoimmune processes triggered by different TLR ligands J Immunol 2013 191 415 423 23720812 48 Ye J Wang Y Liu X Li L Opejin A Hsueh EC TLR7 signaling regulates Th17 cells and autoimmunity: novel potential for autoimmune therapy J Immunol 2017 199 941 954 28652396 49 Peng G Guo Z Kiniwa Y Voo KS Peng W Fu T Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science 2005 309 1380 1384 16123302 50 Kiniwa Y Miyahara Y Wang HY Peng W Peng G Wheeler TM CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer Clin Cancer Res 2007 13 6947 6958 18056169 51 Peng G Wang HY Peng W Kiniwa Y Seo KH Wang RF Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway Immunity 2007 27 334 348 17656116 52 Ye J Huang X Hsueh EC Zhang Q Ma C Zhang Y Human regulatory T cells induce T-lymphocyte senescence Blood 2012 120 2021 2031 22723548 53 Ye J Ma C Hsueh EC Eickhoff CS Zhang Y Varvares MA Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence J Immunol 2013 190 2403 2414 23355732 54 Warburg O On the origin of cancer cells Science 1956 123 309 314 13298683 55 Kim JW Tchernyshyov I Semenza GL Dang CV HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia Cell Metab 2006 3 177 185 16517405 56 Chen C Pore N Behrooz A Ismail-Beigi F Maity A Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia J Biol Chem 2001 276 9519 9525 11120745 57 Kerr EM Gaude E Turrell FK Frezza C Martins CP Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities Nature 2016 531 110 113 26909577 58 Wilde BR Ayer DE Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis Br J Cancer 2015 113 1529 1533 26469830 59 Bhutia YD Babu E Ramachandran S Ganapathy V Amino acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs Cancer Res 2015 75 1782 1788 25855379 60 Yeung SJ Pan J Lee MH Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer Cell Mol Life Sci 2008 65 3981 3999 18766298 61 Beloribi-Djefaflia S Vasseur S Guillaumond F Lipid metabolic reprogramming in cancer cells Oncogenesis 2016 5 e189 26807644 62 Gupta S Roy A Dwarakanath BS Metabolic cooperation and competition in the tumor microenvironment: implications for therapy Front Oncol 2017 7 68 28447025 63 Sitkovsky MV Kjaergaard J Lukashev D Ohta A Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia Clin Cancer Res 2008 14 5947 5952 18829471 64 Sitkovsky M Lukashev D Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors Nat Rev Immunol 2005 5 712 721 16110315 65 Whiteside TL The tumor microenvironment and its role in promoting tumor growth Oncogene 2008 27 5904 5912 18836471 66 Keshari KR Sriram R Van Criekinge M Wilson DM Wang ZJ Vigneron DB Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor Prostate 2013 73 1171 1181 23532911 67 Rodrigues TB Serrao EM Kennedy BW Hu DE Kettunen MI Brindle KM Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose Nat Med 2014 20 93 97 24317119 68 Romero-Garcia S Moreno-Altamirano MM Prado-Garcia H Sanchez-Garcia FJ Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance Front Immunol 2016 7 52 26909082 69 Dietl K Renner K Dettmer K Timischl B Eberhart K Dorn C Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes J Immunol 2010 184 1200 1209 20026743 70 Colegio OR Chu NQ Szabo AL Chu T Rhebergen AM Jairam V Functional polarization of tumour-associated macrophages by tumour-derived lactic acid Nature 2014 513 559 563 25043024 71 Fischer K Hoffmann P Voelkl S Meidenbauer N Ammer J Edinger M Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 2007 109 3812 3819 17255361 72 Brand A Singer K Koehl GE Kolitzus M Schoenhammer G Thiel A LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells Cell Metab 2016 24 657 671 27641098 73 Bopp T Becker C Klein M Klein-Hessling S Palmetshofer A Serfling E Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression J Exp Med 2007 204 1303 1310 17502663 74 Vang T Torgersen KM Sundvold V Saxena M Levy FO Skalhegg BS Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor J Exp Med 2001 193 497 507 11181701 75 Maj T Wang W Crespo J Zhang H Wang W Wei S Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor Nat Immunol 2017 18 1332 1341 29083399 76 Munn DH Mellor AL Indoleamine 2,3 dioxygenase and metabolic control of immune responses Trends Immunol 2013 34 137 143 23103127 77 Murray PJ Allen JE Biswas SK Fisher EA Gilroy DW Goerdt S Macrophage activation and polarization: nomenclature and experimental guidelines Immunity 2014 41 14 20 25035950 78 Ferreira GB Kleijwegt FS Waelkens E Lage K Nikolic T Hansen DA Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells J Proteome Res 2012 11 941 971 22103328 79 Pulendran B Tang H Manicassamy S Programming dendritic cells to induce T(H)2 and tolerogenic responses Nat Immunol 2010 11 647 655 20644570 80 Maldonado RA von Andrian UH How tolerogenic dendritic cells induce regulatory T cells Adv Immunol 2010 108 111 165 21056730 81 Sinclair LV Rolf J Emslie E Shi YB Taylor PM Cantrell DA Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation Nat Immunol 2013 14 500 508 23525088 82 Marelli-Berg FM Fu H Mauro C Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity Immunology 2012 136 363 369 22384794 83 Angela M Endo Y Asou HK Yamamoto T Tumes DJ Tokuyama H Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPARgamma directs early activation of T cells Nat Commun 2016 7 13683 27901044 84 Wang R Dillon CP Shi LZ Milasta S Carter R Finkelstein D The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation Immunity 2011 35 871 882 22195744 85 Berod L Friedrich C Nandan A Freitag J Hagemann S Harmrolfs K De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells Nat Med 2014 20 1327 1333 25282359 86 Zeng H Yang K Cloer C Neale G Vogel P Chi H mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function Nature 2013 499 485 490 23812589 87 Dang EV Barbi J Yang HY Jinasena D Yu H Zheng Y Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1 Cell 2011 146 772 784 21871655 88 De Rosa V Galgani M Porcellini A Colamatteo A Santopaolo M Zuchegna C Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants Nat Immunol 2015 16 1174 1184 26414764 89 Procaccini C Carbone F Di Silvestre D Brambilla F De Rosa V Galgani M The proteomic landscape of human ex vivo regulatory and conventional T cells reveals specific metabolic requirements Immunity 2016 44 406 421 26885861 90 Gerriets VA Kishton RJ Johnson MO Cohen S Siska PJ Nichols AG Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression Nat Immunol 2016 17 1459 1466 27695003 91 Glavan TM Pavelic J The exploitation of Toll-like receptor 3 signaling in cancer therapy Curr Pharm Des 2014 20 6555 6564 25341932 92 Liang X Moseman EA Farrar MA Bachanova V Weisdorf DJ Blazar BR Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells Blood 2010 115 5041 5052 20339095 93 Tye H Kennedy CL Najdovska M McLeod L McCormack W Hughes N STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation Cancer Cell 2012 22 466 478 23079657 94 Kim S Takahashi H Lin WW Descargues P Grivennikov S Kim Y Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis Nature 2009 457 102 106 19122641 95 Song EJ Kang MJ Kim YS Kim SM Lee SE Kim CH Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5 Int J Mol Med 2011 28 115 119 21455558 96 Huang B Zhao J Li H He KL Chen Y Chen SH Toll-like receptors on tumor cells facilitate evasion of immune surveillance Cancer Res 2005 65 5009 5014 15958541 97 Cherfils-Vicini J Platonova S Gillard M Laurans L Validire P Caliandro R Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance J Clin Invest 2010 120 1285 1297 20237413 98 Min R Zun Z Siyi L Wenjun Y Lizheng W Chenping Z Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma Arch Oral Biol 2011 56 877 884 21333270 99 Wang EL Qian ZR Nakasono M Tanahashi T Yoshimoto K Bando Y High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer Br J Cancer 2010 102 908 915 20145615 100 Cammarota R Bertolini V Pennesi G Bucci EO Gottardi O Garlanda C The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker J Transl Med 2010 8 112 21059221 101 Grimmig T Moench R Kreckel J Haack S Rueckert F Rehder R Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and VEGF/PDGF expression in human pancreatic cancer Int J Mol Sci 2016 17 2060 102 Yu T Guo F Yu Y Sun T Ma D Han J Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy Cell 2017 170 548 563 28753429 103 Ito H Ando T Arioka Y Saito K Seishima M Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model Immunology 2015 144 621 630 25322876 104 Von Bubnoff D Scheler M Wilms H Fimmers R Bieber T Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli J Immunol 2011 186 6701 6709 21543643 105 Manches O Munn D Fallahi A Lifson J Chaperot L Plumas J HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism J Clin Invest 2008 118 3431 3439 18776940 106 Everts B Amiel E van der Windt GJ Freitas TC Chott R Yarasheski KE Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells Blood 2012 120 1422 1431 22786879 107 Tannahill GM Curtis AM Adamik J Palsson-McDermott EM McGettrick AF Goel G Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha Nature 2013 496 238 242 23535595 108 Byles V Covarrubias AJ Ben-Sahra I Lamming DW Sabatini DM Manning BD The TSC-mTOR pathway regulates macrophage polarization Nat Commun 2013 4 2834 24280772 109 Everts B Amiel E Huang SC Smith AM Chang CH Lam WY TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation Nat Immunol 2014 15 323 332 24562310 110 Wu D Sanin DE Everts B Chen Q Qiu J Buck MD Type 1 interferons induce changes in core metabolism that are critical for immune function Immunity 2016 44 1325 1336 27332732 111 Saas P Varin A Perruche S Ceroi A Recent insights into the implications of metabolism in plasmacytoid dendritic cell innate functions: potential ways to control these functions F1000Res 2017 6 456 28580131 112 Lachmandas E Boutens L Ratter JM Hijmans A Hooiveld GJ Joosten LA Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes Nat Microbiol 2016 2 16246 27991883 113 Sanin DE Prendergast CT Mountford AP IL-10 production in macrophages is regulated by a TLR-driven CREB-mediated mechanism that is linked to genes involved in cell metabolism J Immunol 2015 195 1218 1232 26116503 114 Cottalorda A Verschelde C Marcais A Tomkowiak M Musette P Uematsu S TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation Eur J Immunol 2006 36 1684 1693 16761317 115 Sutmuller RP den Brok MH Kramer M Bennink EJ Toonen LW Kullberg BJ Toll-like receptor 2 controls expansion and function of regulatory T cells J Clin Invest 2006 116 485 494 16424940 116 Pasare C Medzhitov R Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells Science 2003 299 1033 1036 12532024 117 Reynolds JM Martinez GJ Chung Y Dong C Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation Proc Natl Acad Sci USA 2012 109 13064 13069 22826216 118 Caramalho I Lopes-Carvalho T Ostler D Zelenay S Haury M Demengeot J Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide J Exp Med 2003 197 403 411 12591899 119 Salerno F Guislain A Cansever D Wolkers MC TLR-mediated innate production of IFN-gamma by CD8+ T cells is independent of glycolysis J Immunol 2016 196 3695 3705 27016606 120 Guha M Anticancer TLR agonists on the ropes Nat Rev Drug Discov 2012 11 503 505 22743965 121 Zou W Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 2006 6 295 307 16557261 122 Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 264 22437870 123 Semenza GL Jiang BH Leung SW Passantino R Concordet JP Maire P Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1 J Biol Chem 1996 271 32529 32537 8955077